Historically, blood has been a powerful symbol, conferring familial membership, bestowing the right to rule, and representing human vitality. Throughout both history and literature, from Sleeping Beauty to Harry Potter, a drop of blood has often had immense consequence. Beyond these fantastical purposes, blood is indeed growing in power, with multiple recent advances harnessing the potential of scientific discoveries to use patients' blood to detect a plethora of diseases, from malaria to cancer.
The harnessing of blood to diagnose physical conditions is not new. The complete blood count (CBC) is routine, and blood counting as a diagnostic method has been in use since the 19 th century. Other common blood tests in the clinic include those for liver function, blood glucose levels, and prostate cancer. These tests exploit various components of blood, including cell-free DNA, secreted proteins, and characteristics of blood cells themselves. Using the same underlying premise, but by combining novel scientific discoveries and technological advances, researchers today are greatly expanding the capability of blood tests to illuminate the state of our health.
In a recent study published in Science, Joshua Cohen et al. have advanced the utility of liquid biopsies to detect and even distinguish multiple cancers (Cohen et al., 2018) . The authors developed a new blood test, termed CancerSEEK, which combines assays for 2,001 common driver mutations with assessment of eight cancer-associated protein biomarkers, synergizing to successfully identify eight cancer types at various stages with an overall detection sensitivity of 55%. Excitingly, the results of CancerSEEK, when combined with a supervised machine-learning approach, were sufficient to localize the anatomic site of the tumor in a large majority of cases. Importantly for a screening approach, the test is estimated to cost less than $500, suggesting that Cancer-SEEK and its derivatives may represent cost-effective firstpass diagnostic methodologies for the array of cancer types responsible for 60% of cancer deaths in the United States. However, prospective studies of large populations of individuals over time will be required to fully establish the clinical utility of this blood test for early diagnosis and intervention.
Protein biomarkers, like those utilized in CancerSEEK and the traditional prostate-specific antigen (PSA) test for prostate cancer have long been attractive approaches for cancer diagnosis. However, biomarkers also hold promise for diagnoses beyond malignancy. Indeed, work from Katsuhiko Yanagisawa and colleagues recently published in Nature extends the utility of blood tests for detection of amyloid-b biomarkers for Alzheimer's disease (Nakamura et al., 2018) . Such a simple diagnostic is needed to facilitate clinical trials and drug development, as therapeutic interventions are likely to have strongest effect at early stages of disease, and consistent inexpensive monitoring will provide valuable insight into efficacy. In this work, the authors improve upon prior IP-MS-based methods to detect plasma Ab by creating a composite biomarker consisting of two protein fragment ratios (APP 669-711 /Ab 1-42 and Ab 1-40 /Ab 1-42 ) with improved ability to distinguish Ab + from Ab À patient groups verified by gold-standard imaging diagnosis. The composite biomarker further correlates with levels of brain Ab burden, demonstrating potential utility for clinical screening and longitudinal monitoring.
The CancerSEEK and Alzheimer's disease blood tests together demonstrate the utility of combinatorial approaches, i.e., composite biomarkers, to improve sensitivity and specificity of diagnosis. However, beyond searching for danger signals in the blood, an additional dimension of information that can be leveraged for diagnostics are the qualities of blood cells themselves. In this vein, recent work from Jochen Guck and colleagues harnesses the physical properties of various blood cells to diagnose diseases using a single drop of blood simply diluted in buffer (Toepfner et al., 2018) . By coupling micro-channel blood flow with real-time deformability cytometry, the researchers are able to detect erythrocyte deformation changes caused by spherocytosis or malaria infection, two conditions traditionally diagnosed manually by blood smear followed by secondary assays.
They extend this approach to analyze leukocyte mechanics as a diagnostic, distinguishing morpho-rheological (MORE) characteristics of white blood cells after bacterial and viral infection as well as after malignant transformation. The utility of this approach, which is currently highly sensitive but less specific, will only grow with future discoveries regarding the pathogenesis of myriad conditions that impact MORE characteristics of blood cells, making MORE phenotyping an intriguing clinical advance for a broad array of conditions.
The potential clinical utility for these and other blood tests is substantial. In fact, just last month the FDA approved marketing for the Banyan Brain Trauma Indicator, the first ever blood test to detect mild traumatic brain injury (mTBI) in adults (Federal Drug Administration, 2018) . This test is based on detection of two protein biomarkers, UCH-L1 and GFAP, which are rapidly released in the blood upon traumatic brain injury (www.banyanbio.com). Given the severe consequences of traumatic brain injury, which have been recently highlighted in particular in the context of professional athletes, an inexpensive and rapid first-pass diagnostic is a vast improvement over invasive and expensive CT imaging.
With the rapid pace of discovery in disease pathogenesis research as well as consistent developments in bioengineering and technical invention, the prognosis for blood tests is exceedingly positive. A notable theme from these recent works is the finding that combinatorial approaches are often the most effective, with composite biomarkers universally performing better than single proteins. Thus, it is imperative to continue basic research into disease pathogenesis to extend the toolkit with which scientists can work to develop diagnostics and therapeutics. With improved understanding of the havoc wreaked on our bodies by infection, degeneration and tumorigenesis, scientists will know just what to look for, and complementary technologies will allow them to do so. Hopefully, with just a drop of blood, doctors of the future may be able to detect and understand complex pathologies throughout the human body.
